JPH0329766B2 - - Google Patents
Info
- Publication number
- JPH0329766B2 JPH0329766B2 JP25128884A JP25128884A JPH0329766B2 JP H0329766 B2 JPH0329766 B2 JP H0329766B2 JP 25128884 A JP25128884 A JP 25128884A JP 25128884 A JP25128884 A JP 25128884A JP H0329766 B2 JPH0329766 B2 JP H0329766B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- formula
- antitumor agent
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25128884A JPS61129131A (ja) | 1984-11-28 | 1984-11-28 | サリチル酸誘導体よりなる抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25128884A JPS61129131A (ja) | 1984-11-28 | 1984-11-28 | サリチル酸誘導体よりなる抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61129131A JPS61129131A (ja) | 1986-06-17 |
| JPH0329766B2 true JPH0329766B2 (enEXAMPLES) | 1991-04-25 |
Family
ID=17220572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25128884A Granted JPS61129131A (ja) | 1984-11-28 | 1984-11-28 | サリチル酸誘導体よりなる抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61129131A (enEXAMPLES) |
-
1984
- 1984-11-28 JP JP25128884A patent/JPS61129131A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61129131A (ja) | 1986-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0430924B2 (enEXAMPLES) | ||
| JPH0329766B2 (enEXAMPLES) | ||
| EP0283065A1 (en) | Combinations of FU and BVU as anti-adenocarcinoma agents | |
| EP0394262A1 (en) | PLATINUM COMPOUNDS FOR USE AS PHARMACEUTICALS. | |
| JPH0344049B2 (enEXAMPLES) | ||
| JPH0548207B2 (enEXAMPLES) | ||
| JPH0559892B2 (enEXAMPLES) | ||
| JPH0324446B2 (enEXAMPLES) | ||
| US5369119A (en) | Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon | |
| JPH0513133B2 (enEXAMPLES) | ||
| EP1421942A1 (en) | Use of glycyrrhizin and its derivatives as RANTES inducers | |
| JPH0528690B2 (enEXAMPLES) | ||
| JPH0442368B2 (enEXAMPLES) | ||
| JPH0425933B2 (enEXAMPLES) | ||
| JPH072634B2 (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| JPH0735329B2 (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| JPS61129122A (ja) | アントラニル酸誘導体よりなる抗腫瘍剤 | |
| JPH0120128B2 (enEXAMPLES) | ||
| JPH0616544A (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| JPH0528704B2 (enEXAMPLES) | ||
| JPH0528687B2 (enEXAMPLES) | ||
| JPH0649648B2 (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| JPS61129128A (ja) | 抗腫瘍剤 | |
| JPH02235813A (ja) | 抗腫瘍剤 | |
| JPH0616561A (ja) | 抗レトロウイルス剤 |